205 related articles for article (PubMed ID: 30836910)
1. Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors.
Samanta PN; Kar S; Leszczynski J
Curr Pharm Des; 2019; 25(7):750-773. PubMed ID: 30836910
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.
Lagarias P; Vrontaki E; Lambrinidis G; Stamatis D; Convertino M; Ortore G; Mavromoustakos T; Klotz KN; Kolocouris A
J Chem Inf Model; 2018 Apr; 58(4):794-815. PubMed ID: 29485875
[TBL] [Abstract][Full Text] [Related]
3. Recent Advances in the In-silico Structure-based and Ligand-based Approaches for the Design and Discovery of Agonists and Antagonists of A2A Adenosine Receptor.
Agrawal N; Chandrasekaran B; Al-Aboudi A
Curr Pharm Des; 2019; 25(7):774-782. PubMed ID: 30848185
[TBL] [Abstract][Full Text] [Related]
4. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
[TBL] [Abstract][Full Text] [Related]
5. Structure-based virtual screening discovers potent and selective adenosine A
Matricon P; Nguyen AT; Vo DD; Baltos JA; Jaiteh M; Luttens A; Kampen S; Christopoulos A; Kihlberg J; May LT; Carlsson J
Eur J Med Chem; 2023 Sep; 257():115419. PubMed ID: 37301076
[TBL] [Abstract][Full Text] [Related]
6. Identification of new potent A
Wei Y; Wang M; Li Y; Hong Z; Li D; Lin J
Eur J Med Chem; 2020 Feb; 187():111936. PubMed ID: 31855793
[TBL] [Abstract][Full Text] [Related]
7. Computer-aided design of GPCR ligands.
Gutiérrez-de-Terán H; Keränen H; Azuaje J; Rodríguez D; Åqvist J; Sotelo E
Methods Mol Biol; 2015; 1272():271-91. PubMed ID: 25563191
[TBL] [Abstract][Full Text] [Related]
8. Integrating Pharmacophore into Membrane Molecular Dynamics Simulations to Improve Homology Modeling of G Protein-coupled Receptors with Ligand Selectivity: A2A Adenosine Receptor as an Example.
Zeng L; Guan M; Jin H; Liu Z; Zhang L
Chem Biol Drug Des; 2015 Dec; 86(6):1438-50. PubMed ID: 26072970
[TBL] [Abstract][Full Text] [Related]
9. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.
Ciancetta A; Cuzzolin A; Moro S
J Chem Inf Model; 2014 Aug; 54(8):2243-54. PubMed ID: 25046649
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based Design of Potent and Selective Ligands at the Four Adenosine Receptors.
Jespers W; Oliveira A; Prieto-Díaz R; Majellaro M; Åqvist J; Sotelo E; Gutiérrez-de-Terán H
Molecules; 2017 Nov; 22(11):. PubMed ID: 29125553
[TBL] [Abstract][Full Text] [Related]
11. Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends.
Al-Shar'i NA; Al-Balas QA
Curr Pharm Des; 2019; 25(7):783-816. PubMed ID: 30834825
[TBL] [Abstract][Full Text] [Related]
12. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
Bermudez M; Wolber G
Bioorg Med Chem; 2015 Jul; 23(14):3907-12. PubMed ID: 25828056
[TBL] [Abstract][Full Text] [Related]
13. Recent Updates in the Computer Aided Drug Design Strategies for the Discovery of Agonists and Antagonists of Adenosine Receptors.
Deb PK
Curr Pharm Des; 2019; 25(7):747-749. PubMed ID: 31232230
[No Abstract] [Full Text] [Related]
14. Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.
Mustyala KK; Chitturi AR; Naikal James PS; Vuruputuri U
J Recept Signal Transduct Res; 2012 Apr; 32(2):102-13. PubMed ID: 22384789
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands.
Tintori C; Manetti F; Botta M
Curr Top Med Chem; 2010; 10(10):1019-35. PubMed ID: 20370655
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling approaches for the discovery of adenosine A
Deb PK; Chandrasekaran B; Mailavaram R; Tekade RK; Jaber AMY
Drug Discov Today; 2019 Sep; 24(9):1854-1864. PubMed ID: 31103731
[TBL] [Abstract][Full Text] [Related]
17. Modeling the interactions between alpha(1)-adrenergic receptors and their antagonists.
Du L; Li M
Curr Comput Aided Drug Des; 2010 Sep; 6(3):165-78. PubMed ID: 20412040
[TBL] [Abstract][Full Text] [Related]
18. Biomolecular recognition of antagonists by α7 nicotinic acetylcholine receptor: Antagonistic mechanism and structure-activity relationships studies.
Peng W; Ding F
Eur J Pharm Sci; 2015 Aug; 76():119-32. PubMed ID: 25963024
[TBL] [Abstract][Full Text] [Related]
19. Structural Investigation of Vinca Domain Tubulin Binders by Pharmacophore, Atom based QSAR, Docking and Molecular Dynamics Simulations.
Athar M; Lone MY; Khedkar VM; Radadiya A; Shah A; Jha PC
Comb Chem High Throughput Screen; 2017; 20(8):682-695. PubMed ID: 28486912
[TBL] [Abstract][Full Text] [Related]
20. Targeting the NF-κB/IκBα complex via fragment-based E-Pharmacophore virtual screening and binary QSAR models.
Kanan T; Kanan D; Erol I; Yazdi S; Stein M; Durdagi S
J Mol Graph Model; 2019 Jan; 86():264-277. PubMed ID: 30415122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
